THE European Medicines Agency
has confirmed a review of insomnia
medication zolpidem (Stilnox).
The EMA Pharmacovigilance
Risk Assessment Committee said
it’s reacting to “concerns that
some patients may experience
drowsiness and slower reactions
the day after taking the medicine
which could increase the risk of
accidents during activities that
require alertness, such as driving”.
The review follows a Drug Safety
Communication issued earlier
this year by the US Food and Drug
Administration, lowering the
recommended dose to 5mg for
women and 5-10mg for men.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.